Targeted therapies and small molecule inhibitors are transforming cancer treatment by selectively attacking cancer cells while sparing healthy tissues. These therapies work by interfering with specific molecules involved in cancer growth and progression, such as tyrosine kinases and growth factor receptors. By focusing on molecular pathways unique to cancer cells, targeted therapies reduce systemic toxicity and improve treatment efficacy. Emerging small molecule inhibitors, often used in combination with other treatments, address resistance mechanisms and enhance therapeutic responses, offering hope for improved patient outcomes.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China